5781 RESULTS
Sort By:
As the amyloid pathology is shifting away from blaming predominantly amyloid plaques to now pointing a second accusing finger to smaller, non-deposited aggregates of the Aβ peptide...
The Biology of α-Synuclein and Lewy body Disease Workshop Meeting Cosponsored by NIA and NINDS, Bethesda, Maryland, July 16-17, 2001...
Douglas Smith and his colleagues at the University of Pennsylvania may have filled a gap in research on long-term, neurodegeneration sequelae of brain injuries...
Maas et al. (Abstract 2285) studied how phosphorylation of two different regions in tau proteins affects binding of tau protein to the plasma-membrane (PM). The two major phosphorylation sites studied...
A special interest subgroup meeting on 'Tau protein in Neurodegenerative Diseases' was organized by Gloria Lee, University of Iowa. This was a timely and stimulating meeting...
Zheng et al. (Abstract 516) described the characterization of PAT1, a novel protein that binds to an 11-residue segment of the amyloid precursor protein (APP) in yeast 2-hybrid assays...
Mervyn Monteiro (the author of this report) and colleagues described the identification and characterization of two different proteins that interact with presenilins in the yeast-2 hybrid interaction trap (Y2H)...
Yamaguchi (Abstract 1245) presented his theory that very diffuse plaques within nondemented individuals are cleared by astrocytic phagocytosis. He showed many examples of very diffuse Aβ-positive staining...
Aβ's fibril-formation processes were revealed in a tour de force of atomic force microscopy by Harper (Abstract 909). The initial species to be detected are four nm globular assemblies...
Alonso et al. (Abstract 590) reviewed the role of tau proteins in tubulin polymerization. There are six tau isoforms in the human brain. Three have three microtubule-binding domains (3R) and the three others have four microtubule-binding domains (4R)...
In Year Three, GAP Trial Network Is Starting to Hum Getting to Go: GAP-Net Sets Sight on Faster Start Three years after the Global Alzheimer’s Platform (GAP) Foundation launched GAP-Net, a standing network of clinical trial sites optimized for Alzheimer’s ...
From central IRBs, certified raters, to local transport: Changes large and small are needed to ramp up drug testing in Alzheimer’s.
Award recognizes his contributions to basic and clinical research.
With three trials and initiatives to boost recruitment, GAP-Net is gaining some traction in the field.
Experts said Phase 3 data did not prove the device could slow AD.
